Targovax - Småprat 2 (TRVX) 1

[Longtrader]

@ufo

Reperasjons-emi blir vedtatt.

Nei, den kan sløyfes. Bare bortkastet tid.

Edit: Egentlig kan de bare levere resultatet , også bli enig om oppkjøp.

[ufo]

Er helt enig men det er vel ikke noe valg.
Det er vel nedfelt i selskapets kjøreregler.

Men , husker PCIB sin repemi for noen år siden , det var jo en eventyrlig opplevelse å være småaksjonær den gangen.

Det blir penger av slikt

[ufo]

tror du må lenger tilbake i tid

[TyrionIV]

Pcib har ikke hatt repemi.
De har kun kjørt fortrinnsrettet emi med (omsettbare) tegningsretter mot eksisterende aksjonærer…
Hadde fortrinnsrettet emi på 10 kr, 7 kr og 30 kr de tre siste ihvertfall…
Det var antakelig den på 7 som omtales av ufo… (veldig off topic nå, beklager det)

[Legoland]

Beklager, feil tråd.

[Takk]

Pcib Emi desember 2016 er vel den som var en god opplevelse

[dri]

Jepp. 5000 kr/aksje og jeg selger umiddelbart!

[Domboshawa]

Feil tråd folkens!

[TekBot]

Notice of Annual General Meeting

The Annual General Meeting of Targovax ASA (the “Company”) will be held at the
Company’s offices at Lysaker, on 17 March 2021 at 10:00 CET.

…

Vis børsmeldingen

As a consequence of the extraordinary situation related to the corona virus the
Company encourages shareholders not to attend the general meeting in person, but
rather to make use of the ability to cast an advance vote or to vote by proxy.

Corona measures
The Company will hold the general meeting in such a way as to minimize the risk
of infection as much as possible and will take such measures as may be necessary
to comply with governmental regulations in connection with the general meeting.

The Annual General Meeting will be conducted as briefly as possible, and
representation of Targovax’s Board of Directors and administration will be kept
to a minimum.

No refreshments will be served and necessary infection prevention measures will
be taken for shareholders attending in person.

Notice of attendance
Notice of attendance must be received no later than 15 March 2021 at 16:00 CET.

Casting of advance votes and submission of proxies must be received no later
than 15 March 2021 at 16:00 CET.

Attached you will find the notice to the General Meeting, including appendices.
The notice and appendices will also be made available on Targovax’ website
General Meetings – Targovax.

TRVX - Notice AGM 17 March
2021.pdf (https://mb.cision.com/Public/17093/3288942/ae2b091305cdb000.pdf)

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About TargovaxActivating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer
indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.

Kilde

[Klomp]

Søker fullmakt til 40 prosent økning ja…

[Celestar]

Drt er jo helt normalt og ikke så veldig oppsiktsvekkende…

[Krieghoff]

Så flink du er når det er det du velger å fokusere på i dagens melding. Trur du finner noe annet som er betydelig viktigere

[solskimm]

Forslag på nytt styremedlem, Sonia Quaratino:

https://www.businessweekly.co.uk/news/recruitment/former-novartis-and-merck-ace-kymab’s-first-cmo

Sonia Quaratino, MD PhD

Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal...

Vi må jo fortsatt ikke glemme Damian Marron:

Styret begynner å samle på en type erfaring hos de nyeste styremedlemmene, hvorfor det mon tro?

[Krieghoff]

Helt ærlig så må de gjerne be om 100% fullmakt for min del. Det som er viktig for meg er kursen emisjonen settes på

[TekBot]

Targovax ASA: Fourth quarter 2020 results

Oslo, Norway, 18 February 2021 - Targovax ASA (OSE: TRVX), a clinical stage
biotechnology company developing immune activators to target hard-to-treat solid
tumors, today announces its fourth quarter 2020 results.
…

Vis børsmeldingen

Targovax will host a Capital Markets Day for investors, analysts and the press
at 14:30 CET today, which will include a fourth quarter update (details below).

FOURTH QUARTER HIGHLIGHTS

DATA

· Announced impressive objective responses as well as effects on non-injected
lesions in ONCOS-102 trial in anti-PD1 refractory melanoma patients

· Demonstrated encouraging survival data for ONCOS-102 in mesothelioma

· Presented an abstract on the 12-month analysis of biomarkers and clinical
outcome from the phase I/II trial in malignant pleural mesothelioma at the
Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

CORPORATE

· Completed a private placement, raising gross proceeds of approximately NOK
75 million (USD 8 million). The Private Placement attracted strong interest from
existing shareholders and new institutional investors, both in the Nordics and
internationally, and the transaction was oversubscribed multiple times

· Announced grant of European Patent no 3293201 by the European Patent Office.
The patent covers the use of ONCOS-102 in combination with checkpoint inhibitors
until 2036

· Formed a new Scientific Advisory Board (SAB), consisting of a group of world
-renowned experts in immuno-oncology research and drug development carefully
selected to act as advisors to guide the Targovax R&D strategy

FINANCIALS

                    Unaudited  Unaudited

Amounts in NOK 4Q 2020 4Q 2019 FY 2020 FY 2019
thousands

Total operating - 2 234 624 2 251
revenues
Total operating -22 872 -41 577 -104 524 -152 524
expenses
Operating -22 872 -39 344 -103 901 -150 273
profit/loss
Net financial items -3 413 4 501 -4 503 2 422
Income tax 57 72 277 321
Net profit/loss -26 229 -34 770 -108 126 -147 529

Basic and diluted -0.31 -0.55 -1.40 -2.43
EPS (NOK/share)

Net change in cash 44 665 -33 590 51 893 -80 760
Cash and cash 77 657 104 019 70 429 151 189
equivalents start of
period
Cash and cash 122 321 70 429 122 321 70 429
equivalents end of
period

RECENT HIGHLIGHTS

·
Received Fast-Track designation for ONCOS-102 in malignant pleural mesothelioma

·
Entered a research collaboration with Papyrus Therapeutics to develop novel
ONCOS viruses with receptor tyrosine kinase (RTK) inhibitor functionality

·
Collaboration partner SOTIO stopped the combination trial assessing the
combination of ONCOS-102 and DCVAC/PCa in prostate cancer due to slow patient
recruitment. Only a very limited patient population fulfilled the strict
inclusion criteria. Therefore, the recruitment could not meet originally planned
numbers

·
Granted IOVaxis 3 months extension to the exclusive license option for TG mutant
RAS vaccines in Greater China and Singapore

Øystein Soug, CEO commented: “2020 has been a special year in many aspects and
the COVID-19 pandemic made quite an impact on our lives. Luckily, in Targovax we
have so far been able to cope well, and 2020 brought us considerably closer to
our goal of being able to bring important clinical benefit to cancer patients,
and thus extend and transform their lives. Class-leading melanoma data, improved
mesothelioma survival outcomes, compelling immune activation, an expanding
pipeline and a rejuvenated mutant RAS program provide us with a solid platform
to reach this goal. Our successes were made possible by the impressive efforts
from our hard-working team, and our world leading partners.”

Presentation
As a consequence of the Corona situation, there will not be a physical
presentation of the results. Instead, we invite to the live Capital Markets Day
webcast today at 14.30 CET. You can join the webcast
here (Capital markets day 2021 – Targovax). It will be
possible to ask questions during the presentation.
Reporting material
2102 TRVX Q4 report
final.pdf (https://mb.cision.com/Public/17093/3289125/a8a30bee01bbb5b3.pdf)
The quarterly report is also available at
www.targovax.com (Financial Reports – Targovax).

---

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer
indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.

Kilde

[TekBot]

Targovax ASA: Annual Report 2020

On 17 February 2021, the Board of Directors of Targovax ASA approved the
Company’s financial statements for 2020, which will be processed at the
Company’s annual general meeting on 17 March 2021. The Company’s annual accounts
…

Vis børsmeldingen

for the financial year 2020, including the financial statements and annual
report for the financial year 2020, are together with the auditor’s report
attached to this notice. The documents are also available at the Company’s
website, www.targovax.com (Financial Reports – Targovax)
Targovax Annual Report
2020.pdf (https://mb.cision.com/Public/17093/3289155/a319d866f5c22b01.pdf)

---

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com
Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

IR enquires:
Kim Sutton Golodetz - LHA Investor Relations (US)
Email: kgolodetz@lhai.com
Phone: +1 212-838-3777

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax aims to unlock
greater clinical benefits in cancer patients by deploying multifunctional
platforms to target key immune regulators and oncogenic drivers. Targovax’s
focus is to “activate the patient’s immune system to fight cancer”, thus
extending and transforming the lives of cancer patients with targeted
therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer
indications, including melanoma, mesothelioma and colorectal cancer. The
products are designed to harness the patient’s own immune system to fight the
cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system to fight the cancer. On the back of very
encouraging data in several indications, in monotherapy and in multiple
combination, the next development steps for ONCOS-102 will involve a clinical
trial with registration intent in checkpoint inhibitor refractory melanoma.

Kilde

[Moborg]

Soug: "Class-leading melanoma data, improved mesothelioma survival outcomes, compelling immune activation, an expanding pipeline and a rejuvenated mutant RAS program provide us with a solid platform to reach this goal.

Our successes were made possible by the impressive efforts from our hard-working team, and our world leading partners.”

[Whatsthat]

Based on these promising and class-leading results, Targovax intends to move on to a registration-
directed trial. The company believes a single arm trial with 125-150 patients in confirmed anti-PD1
refractory melanoma patients could support an accelerated approval, subject to sufficient clinical
benefit

From the ONCOS-200-series we have selected ONCOS-211 as the lead candidate for further development. ONCOS-211 carries two transgenic payloads, inducible costimulator-ligand (ICOS-L) and adenosine deaminase (ADA).

[1mattis1]

Så…, det tyder, så langt, at penger må hentes inn via en rettet emisjon?

[solvoll]

The future of ONCOS-102
With a robust data set that confirms the clinical activity of ONCOS-102 in multiple cancer types
and versatility as combination therapy, we have started drawing up the next stage of
development. The decisions we make now will define the benefit delivered to patients and value
created for shareholders and shape the company for years to come.

With stellar data in melanoma, our top priority for 2021 will be to rapidly initiate a registration-
directed trial combining ONCOS-102 with an anti-PD1 checkpoint inhibitor in this indication. In
parallel, we will evaluate agile and cost-effective opportunities to bring ONCOS-102 forward in
mesothelioma, colorectal cancer and/or other indications, thus retaining multiple shots on goal.

Direktelink til Q4 rapporten

a8a30bee01bbb5b3.pdf